Skip to main
  1. Stocks
  2. Aytu BioScience
  3. Forecast
AYTU

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma is supported by an improving operating profile, with fiscal Q4 FY26 revenue of $16.1 million, up 6% year over year and well ahead of estimates, while pro forma EPS of $0.03 beat expectations by a wide margin. The company’s outlook is anchored by EXXUA, a first-in-class FDA-approved treatment for adult MDD that launched in Q4 2025 and has shown a highly encouraging early reception, backed by a differentiated side-effect profile and clinical data from more than 5,000 patients. With EXXUA targeting the $22 billion U.S. prescription MDD market and management’s conservative FY27 revenue expectations of $68 million to $70 million, the stock offers meaningful growth leverage if commercialization continues to gain traction.

Bears say

Aytu BioPharma is facing a weak fundamental backdrop, as fiscal Q3 FY26 revenue fell 33% year over year to $12.4 million, highlighting sharp top-line deterioration despite narrowly beating estimates of $12.0 million and consensus of $12.1 million. Profitability remains under pressure, with pro forma EPS of $(0.43) coming in worse than the estimate of $(0.31), underscoring that losses are still widening or proving difficult to contain. The lack of Q3 guidance adds to the negative outlook because it limits visibility into near-term execution and suggests management may not have confidence in an immediate turnaround.

Aytu BioScience (AYTU) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Aytu BioScience (AYTU) Analyst Forecast & Price Prediction

Get the latest Aytu BioScience (AYTU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aytu BioScience (AYTU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Buy based on their latest research and market trends.

According to 2 analysts, Aytu BioScience (AYTU) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Aytu BioScience (AYTU) Analyst Forecast & Price Prediction

Get the latest Aytu BioScience (AYTU) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aytu BioScience (AYTU)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AYTU stock data and trends